创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

LI Yongling, SUN Zhenliang. Research Progress in Anti-tumor Activities of STAT3 Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(3): 226-231.
Citation: LI Yongling, SUN Zhenliang. Research Progress in Anti-tumor Activities of STAT3 Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(3): 226-231.

Research Progress in Anti-tumor Activities of STAT3 Inhibitors

  • Signal transducers and activators of transcription 3 (STAT3) is a transcription factor involved in a variety of biological functions, which conducts extracellular signals to the nucleus, thus activating transcription of target genes. Abnormal activation of STAT3 induces tumorigenesis and promotes tumor development. It has been shown to be an attractive anticancer target. Currently, studies on STAT3 inhibitors are developing rapidly, mainly including STAT3 upstream signal inhibitors and STAT3 direct inhibitors. Recent research progress in anti-tumor activities of drugs targeting STAT3 has been reviewed in this paper.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return